Royalty Pharma and Cytokinetics have announced a strategic funding collaboration worth up to $575 million. This partnership is aimed at supporting the commercialization of Cytokinetics’ drug aficamten, a cardiac myosin inhibitor, and advancing its cardiovascular pipeline. The collaboration includes an immediate $250 million, with additional funding contingent on various milestones. Funding components involve commercial launch financing, royalty restructuring, development funding for pivotal clinical trials, and equity purchases. This deal marks the third transaction between the two companies, highlighting Royalty Pharma’s capability to structure comprehensive, mutually beneficial financial solutions. Legal advisors for the deal included several law firms such as Goodwin Procter LLP and Cooley LLP, while Evercore acted as a financial advisor for Cytokinetics.

Biopharmaceutical, Private Equity,United States, Global

Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline